Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Q: How long will it take to read this news story?

The story "Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast" has 665 words across 32 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast" was covered 9 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 317 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #25280171</li><li>URL: https://beamstart.com/news/zydus-life-up-2-on-17373636768785</li></ul>

Business Standard Logo Business Standard 9h ago

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast - Business Standard

Quick Summary:

ALS affects approximately 32,000 people in the USA and on an average 5,000 new patients are diagnosed every year with this disease in USA as per statistics from Centre for Disease Control and Prevention (CDC).

At 2:00 PM, Zydus Life shares were trading 0.32 per cent lower at Rs 991 per share.

The Phase 2(b), randomized, double-blind, placebo-controlled, parallel-group, multicentre study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with ALS.